Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

January 2, 2024

PASADENA, Calif.--(BUSINESS WIRE)--Jan. 2, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Dane Leone, CFA, has joined Xencor as senior vice president, corporate strategy. In this newly created role, Mr. Leone will support the Company's R&D leadership to enhance value across Xencor's platform technologies by overseeing assessment and prioritization of Xencor's current and future XmAb ® drug candidates. Mr. Leone has 20 years of experience as a leading equity research analyst, most recently as a managing director and senior biotechnology analyst at Raymond James.

"At Xencor, we continuously assess emerging clinical data from our pipeline programs and the rapidly evolving competitive landscape to optimize our resource allocation. Dane's strong track record of generating unique and insightful industry analyses, along with engaging closely with clinicians and capital market participants, complements our research and clinical development organizations and makes him an important addition to our team," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "We are grateful to have Dane on board and anticipate his contributions will help maximize the utility of our platforms and the value of our clinical programs."

"Beyond the validation of three commercialized medicines, Xencor's XmAb ® platforms have yielded a portfolio of internal and external drug candidates using novel biological mechanisms to address challenging clinical problems," said Mr. Leone. "I look forward to working with Xencor's R&D team to harness this approach for the greatest value impact, advancing promising potential treatment options for patients with cancer and other serious diseases."

Mr. Leone's focus areas in equity research included oncology, immunology, cardiology and ophthalmology. His coverage spanned securities across a wide range of market capitalization, from biotechnology companies advancing a diverse set of drug candidates to commercializing novel medicines. Before Raymond James, Mr. Leone held analyst roles with increasing seniority at BTIG and Macquarie Securities Group. He began his career in portfolio management as a health care and quantitative research analyst at AllianceBernstein. Mr. Leone received his B.S. in business from the State University of New York at Albany. He holds the Chartered Financial Analyst® designation from the CFA® Institute.

CFA® and Chartered Financial Analyst® are registered trademarks of CFA Institute.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Forward-Looking Statements

Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committed," "investigational," and similar terms, or by express or implied discussions relating to Xencor's business, including, but not limited to the quotations from Xencor's president and chief executive officer, quotations from Xencor's senior vice president, corporate strategy and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks, including the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, in each case as described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2022 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240102974799/en/

Charles Liles
cliles@xencor.com
626-737-8118

For Media:
Jason I. Spark
Evoke Canale
jason.spark@evokegroup.com
619-849-6005

Source: Xencor, Inc.